Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Xu, Yinchuan ^a   Hu, Xinyang ^a   Wang, Lihan ^a   Jiang, Zhi ^a   Liu, Xianbao ^a   Yu, Hong ^a   Zhang, Zhaocai ^a   Chen, Huiqiang ^a   Chen, Han ^a   Steinhoff, Gustav ^b   Li, Jun ^c   Wang, Jian'an ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; NITRIC OXIDE; VALSARTAN;

ACUTE HEART INFARCTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD VESSEL DENSITY; BLOOD VESSEL PARAMETERS; CELL PROTECTION; CELL SURVIVAL; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; MONONUCLEAR CELL; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; TISSUE REPAIR; TREATMENT OUTCOME;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CELL TRANSPLANTATION; COCULTURE TECHNIQUES; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; STEM CELL TRANSPLANTATION; TETRAZOLES; VALINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892400320     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082997     Document Type: Article

References (35)

1. Nabel EG, Braunwald E (2012) A tale of coronary artery disease and myocardial infarction. N Engl J Med 366: 54-63. doi:10.1056/NEJMra1112570. PubMed: 22216842.
2. Gnecchi M, Danieli P, Cervio E (2012) Mesenchymal stem cell therapy for heart disease. Vascul Pharmacol 57: 48-55. doi:10.1016/j.vph. 2012.04.002. PubMed: 22521741.
3. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A et al. (2012) Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2: CD006536. PubMed: 22336818.
4. Tongers J, Losordo DW, Landmesser U (2011) Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 32: 1197-1206. doi:10.1093/eurheartj/ehr018. PubMed: 21362705.
5. Menasche P (2011) Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 50: 258-265. doi:10.1016/j.yjmcc.2010.06.010. PubMed: 20600097.
6. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME et al. (2008) Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 135: 799-808. doi:10.1016/j.jtcvs.2007.07.071. PubMed: 18374759.
7. Hoke NN, Salloum FN, Kass DA, Das A, Kukreja RC (2012) Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells 30: 326-335. doi:10.1002/stem.789. PubMed: 22102597.
8. Mangi AA, Noiseux N, Kong D, He H, Rezvani M et al. (2003) Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 9: 1195-1201. doi: 10.1038/nm912. PubMed: 12910262.
9. Haider KH, Ashraf M (2012) Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol. Transl Sci 111: 323-356.
10. Gajarsa JJ, Kloner RA (2011) Left ventricular remodeling in the postinfarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 16: 13-21. doi:10.1007/s10741-010-9181-7. PubMed: 20623185.
11. Matsubara H (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182-1191. doi:10.1161/01.RES.83.12.1182. PubMed: 9851935.
12. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M et al. (2008) Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532. doi:10.1161/CIRCULATIONAHA. 108.784868. PubMed: 19029468.
13. Strawn WB, Richmond RS, Ann Tallant E, Gallagher PE, Ferrario CM (2004) Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 126: 120-126. doi: 10.1111/j.1365-2141.2004.04998. x. PubMed: 15198742.
14. Iwanami J, Mogi M, Li JM, Tsukuda K, Min LJ et al. (2008) Deletion of angiotensin II type 2 receptor attenuates protective effects of bone marrow stromal cell treatment on ischemia-reperfusion brain injury in mice. Stroke 39: 2554-2559. doi:10.1161/STROKEAHA.107.513275. PubMed: 18617657.
15. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A et al. (2011) Effect of angiotensin II type 2 receptor deletion in hematopoietic cells on brain ischemia-reperfusion injury. Hypertension 58: 404-409. doi:10.1161/ HYPERTENSIONAHA.111.177873. PubMed: 21768524.
16. Calvert JW, Lefer DJ (2009) Myocardial protection by nitrite. Cardiovasc Res 83: 195-203. doi:10.1093/cvr/cvp079. PubMed: 19251721.
17. Yayama K, Hiyoshi H, Imazu D, Okamoto H (2006) Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension 48: 958-964. doi:10.1161/01.HYP.0000244108.30909.27. PubMed: 17000928.
18. Li J, Zhao X, Li X, Lerea KM, Olson SC (2007) Angiotensin II type 2 receptor-dependent increases in nitric oxide synthase expression in the pulmonary endothelium is mediated via a G alpha i3/Ras/Raf/MAPK pathway. Am J Physiol Cell Physiol 292: C2185-C2196. doi:10.1152/ajpcell.00204.2006. PubMed: 17329403.
19. Wen Z, Zheng S, Zhou C, Wang J, Wang T (2011) Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med 15: 1032-1043. PubMed: 21199333.
20. Ranganath SH, Levy O, Inamdar MS, Karp JM (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10: 244-258. doi:10.1016/j.stem.2012.02.005. PubMed: 22385653.
21. Bona RD, Liuzzo G, Pedicino D, Crea F (2011) Anti-inflammatory treatment of acute coronary syndromes. Curr Pharm Des 17: 4172-4189. doi:10.2174/ 138161211798764771. PubMed: 22204377.
22. van der Laan AM, Piek JJ, van Royen N (2009) Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 6: 515-523. doi:10.1038/nrcardio.2009.103. PubMed: 19528962.
23. Lovell MJ, Yasin M, Lee KL, Cheung KK, Shintani Y et al. (2010) Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. Atherosclerosis 213: 67-76. doi:10.1016/j. atherosclerosis.2010.07.045. PubMed: 20810112.
24. Yoon CH, Koyanagi M, Iekushi K, Seeger F, Urbich C et al. (2010) Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment. Circulation 121: 2001-2011. doi:10.1161/CIRCULATIONAHA. 109.909291. PubMed: 20421519.
25. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A et al. (2004) Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109: 1615-1622. doi:10.1161/01.CIR. 0000124476.32871.E3. PubMed: 15037527.
26. Ludwig M, Steinhoff G, Li J (2012) The regenerative potential of angiotensin AT2 receptor in cardiac repair. Can J Physiol Pharmacol 90: 287-293. doi:10.1139/y11-108. PubMed: 22364522.
27. Numasawa Y, Kimura T, Miyoshi S, Nishiyama N, Hida N et al. (2011) Treatment of human mesenchymal stem cells with angiotensin receptor blocker improved efficiency of cardiomyogenic transdifferentiation and improved cardiac function via angiogenesis. Stem Cells 29: 1405-1414. PubMed: 21755575.
28. Altarche-Xifró W, Curato C, Kaschina E, Grzesiak A, Slavic S et al. (2009) Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells 27: 2488-2497. doi:10.1002/stem.171. PubMed: 19591228.
29. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J et al. (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci U S A 103: 14537-14541. doi:10.1073/pnas.0604144103. PubMed: 16983080.
30. Coyne TM, Marcus AJ, Woodbury D, Black IB (2006) Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells 24: 2483-2492. doi:10.1634/stemcells.2006-0174. PubMed: 16873764.
31. Benndorf R, Böger RH, Ergün S, Steenpass A, Wieland T (2003) Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. Circ Res 93: 438-447. doi:10.1161/01.RES. 0000088358.99466.04. PubMed: 12881481.
32. Min JY, Sandmann S, Meissner A, Unger T, Simon R (1999) Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction. J Pharmacol Exp Ther 291: 1038-1044. PubMed: 10565822.
33. Leenen FH, Huang BS, Yu H, Yuan B (1995) Brain 'ouabain' mediates sympathetic hyperactivity in congestive heart failure. Circ Res 77: 993-1000. doi:10.1161/01.RES.77.5.993. PubMed: 7554154.
34. Yasuda T, Weisel RD, Kiani C, Mickle DA, Maganti M et al. (2005) Quantitative analysis of survival of transplanted smooth muscle cells with real-time polymerase chain reaction. J Thorac Cardiovasc Surg 129: 904-911. doi:10.1016/j.jtcvs.2004.06.027. PubMed: 15821662.
35. Krishnamurthy P, Rajasingh J, Lambers E, Qin G, Losordo DW et al. (2009) IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104: e9-18. doi:10.1161/CIRCRESAHA. 108.188243. PubMed: 19096025.